Baxalta Gets FDA Approval for State-of-the-Art Singapore Facility

Nov 17, 2015

Baxalta, a Baxter International spin off formed in July, announced that its state-of-the-art recombinant biologic manufacturing facility in Singapore received U.S. FDA approval to manufacture bulk drug substance for Advate, Baxalta’s market leading treatment for hemophilia A.

The approval comes after a successful filing and site audit with zero observations, confirming that the site complies with all Good Manufacturing Practices.

According to Baxalta, this site approval is a key milestone in the Illinois-based biopharmaceutical company's manufacturing strategy, enabling continued growth of its global Factor VIII portfolio, including Advate and additional investigational treatments.

Read the Baxalta press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments